Investment Rating - The report maintains a "Strong Buy" rating for several companies in the innovative drug sector, particularly highlighting the growth potential of companies like 加科思 (JAK-23E73) and others in the medical device and life sciences service sectors [10][15][17]. Core Insights - The innovative drug sector in China is experiencing high-quality growth, significantly outpacing global averages, with a focus on domestic companies gaining international market share [10]. - The medical device industry is seeing a recovery in bidding scales and a shift towards innovation, with companies like 迈瑞医疗 and 澳华内镜 being recommended for investment [15]. - The life sciences service sector is expected to rebound as demand increases, driven by both domestic and international markets, with companies like 百普赛斯 and 药康生物 highlighted for their growth potential [17]. Summary by Sections Market Review - The medical index increased by 1.49%, outperforming the沪深300 index by 2.9 percentage points, ranking 5th among 30 sectors [7]. - Top-performing stocks included 美诺华 and 万邦德, while stocks like 科源制药 and 长药退 faced significant declines [6][30]. Innovative Drugs - China has become a key player in global innovative drug development, with a notable increase in overseas licensing deals, suggesting a shift towards an "innovation-driven" revenue era [10]. - Recommended companies include 百利天恒, 百济神州, and 恒瑞医药, among others [10]. Medical Devices - The high-value consumables sector is seeing easing pressure from centralized procurement, with companies like 春立医疗 and 迈普医学 recommended for their growth potential [15]. - The medical equipment sector is expected to experience a recovery, with significant growth anticipated in 2025 [15]. Life Sciences Services - The sector is poised for a rebound, with increasing demand from both domestic and international markets, and companies like 百普赛斯 and 药康生物 are expected to benefit [17]. Traditional Chinese Medicine - The report emphasizes the importance of basic drugs and state-owned enterprise reforms, recommending companies like 昆药集团 and 康缘药业 for their growth potential [21]. Pharmacy Sector - The pharmacy sector is expected to benefit from the acceleration of prescription outflow and an improved competitive landscape, with companies like 老百姓 and 益丰药房 highlighted for investment [18]. Medical Services - The report suggests a positive outlook for private medical services, particularly for companies like 固生堂 and 爱尔眼科, due to market improvements and expanding insurance coverage [20].

Investment Rating - The report maintains a "Strong Buy" rating for several companies in the innovative drug sector, particularly focusing on those with promising pipelines and market potential [14]. Core Insights - The innovative drug sector in China is experiencing high-quality growth in research and development, significantly outpacing global averages. This trend positions China as a key player in the global innovative drug market [10]. - The medical device sector is seeing a recovery in bidding scales and a shift towards innovation, with companies like Mindray Medical and Aohua Endoscopy being highlighted for their growth potential [15]. - The life sciences service sector is expected to rebound as demand increases, driven by both domestic and international markets, with companies like BGI Genomics and Nanwei Technology being recommended for investment [17]. - The pharmacy sector is poised for growth due to the acceleration of prescription outflow and an improving competitive landscape, with companies like YaoBaiYao and YiFeng Pharmacy being noted as key players [18]. Summary by Sections Market Review - The medical index rose by 1.49%, outperforming the CSI 300 index by 2.9 percentage points, ranking fifth among 30 sectors [7]. - Top-performing stocks included Meinuohua and Wanbangde, while stocks like Keyuan Pharmaceutical and Changyao Tui faced significant declines [30]. Innovative Drugs - The report emphasizes the importance of innovative drugs, with a focus on companies like BeiGene and Hengrui Medicine, which are expected to benefit from global market expansion [10][14]. - The collaboration between companies like JAK-23E73 and AstraZeneca is highlighted as a significant advancement in the innovative drug pipeline [14]. Medical Devices - The report notes a recovery in the medical device sector, with a focus on high-value consumables and the internationalization of domestic companies [15]. - Companies such as Mindray Medical and Aohua Endoscopy are recommended for their innovative products and growth potential in both domestic and international markets [15]. Life Sciences Services - The life sciences service sector is expected to see a recovery in demand, with companies like BGI Genomics and Bioplus being highlighted for their growth potential [17]. - The report indicates that the sector's profitability is expected to improve as revenue growth resumes [17]. Pharmacy Sector - The pharmacy sector is expected to benefit from the acceleration of prescription outflow and an improved competitive landscape, with companies like YaoBaiYao and YiFeng Pharmacy being recommended for investment [18]. - The report suggests that the integration of online and offline pharmacy services will enhance competitiveness [18]. Traditional Chinese Medicine - The report highlights the potential for growth in traditional Chinese medicine, particularly in basic drug categories and state-owned enterprise reforms [21]. - Companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical are recommended for their strong market positions [21]. Medical Services - The report suggests that the medical services sector will benefit from anti-corruption measures and the expansion of private healthcare, with companies like Gushengtang and Aier Eye Hospital being noted for their growth potential [20]. Blood Products - The report indicates that the blood products sector is expected to see growth due to relaxed approval processes and increasing demand, with companies like Tiantan Biological Products being highlighted [12].

Core Viewpoint - The report emphasizes the growth potential in the pharmaceutical industry, particularly in innovative drugs, medical devices, and life sciences services, driven by domestic and international market dynamics [8][10][15]. Market Review - The CITIC Pharmaceutical Index rose by 1.49%, outperforming the CSI 300 Index by 2.9 percentage points, ranking 5th among 30 primary industries [6]. - Top-performing stocks included Meinuohua and Wanbangde, with increases of 40.73% and 38.81% respectively, while stocks like Keyuan Pharmaceutical and Changyao Tui saw declines of 19.92% and 18.18% [6][25]. Sector Insights and Investment Strategy - **Innovative Drugs**: China is becoming a significant player in global innovative drug development, with a notable increase in overseas licensing deals, suggesting a shift towards an "innovation-driven" revenue era [8]. - **Medical Devices**: The pressure from high-value consumables procurement is easing, and the industry is expected to see a recovery in revenue growth by Q3 2025. Companies are focusing on international expansion and technological upgrades [8][13]. - **Life Sciences Services**: The sector is witnessing a recovery in demand, with a projected increase in revenue starting from Q4 2024. The focus is on domestic and international market expansion [15][17]. - **Traditional Chinese Medicine**: The market for essential medicines is expected to grow, particularly as the new medical insurance directory expands coverage [9][18]. - **Pharmacy Sector**: The trend of prescription outflow is expected to accelerate, improving the competitive landscape for pharmacies [16]. Earnings Forecast for Q1 2026 - Various companies are projected to have modest revenue growth, with notable predictions including: - Kanglong Chemical: 10-15% revenue growth - Aier Eye Hospital: 0-10% revenue growth - Yifeng Pharmacy: 0-5% revenue growth [10]. Key Events in the Industry - The approval of Tezepelumab for asthma treatment in China marks a significant milestone for AstraZeneca and Amgen [24]. - The construction of the Longhua International Medical Device City aims to enhance the high-end medical device industry in China [23]. Conclusion - The pharmaceutical industry is poised for growth, driven by innovation, regulatory changes, and market dynamics, with specific sectors like innovative drugs and medical devices showing promising potential for investment [8][10][15].

Group 1 - The company announced on March 20, 2026, that its subsidiary, Tiantan Shanghai, received the "High-tech Enterprise Certificate," allowing it to enjoy a corporate income tax rate of 15% for three consecutive years (2025, 2026, 2027) [4] Group 2 - The company emphasizes innovation and R&D, with multiple products making significant progress. As of mid-2025, "Rongsheng" fourth-generation static gamma globulin received approval, while several other products are in various stages of clinical trials [5] Group 3 - The company maintains a leading position in plasma collection, achieving 1,361 tons of plasma collection from 85 operational plasma stations in the first half of 2025, accounting for approximately 20% of the domestic market [6] - The company has completed construction of several projects, including the Yong'an plant and Yunnan project, with a future design capacity for blood products exceeding 5,000 tons, ensuring continued leadership in production scale and sales revenue [6]

Core Viewpoint - The Jiangsu provincial government has released the "Action Plan for Promoting High-Quality Urban Development in Jiangsu," aiming to build modern, innovative, livable, beautiful, resilient, civilized, and smart cities, making them happy homes for the people [1][4]. Group 1: Implementation of Central Policies - The "Action Plan" aligns with the central government's urban development strategies, addressing the transition from rapid urbanization to stable development and from large-scale expansion to quality enhancement [2][8]. - It emphasizes promoting urban connotation development through a framework of "one optimization and six constructions" to ensure effective implementation of national policies in Jiangsu [2][8]. Group 2: Urban Layout Optimization - The "Action Plan" outlines a three-tier structure for urban development: - At the urban agglomeration level, it focuses on networked development, enhancing the international competitiveness of the Yangtze River Delta urban agglomeration [3][9]. - At the city level, it aims to improve core functions by increasing economic density and attracting high-end talent and financial resources [3][9]. - At the county level, it seeks to enhance service capabilities and promote urbanization through various initiatives [3][9]. Group 3: Innovation-Driven Development - The "Action Plan" places "innovation-driven" at the core of urban development, recognizing Jiangsu's status as a major economic and technological innovation hub [4][10]. - It includes seven specific tasks focused on fostering innovation, which constitutes 25% of the total tasks, highlighting the commitment to empower urban development through innovation [4][10]. Group 4: Talent Development - The "Action Plan" emphasizes building a talent-friendly city, investing in human resources across various levels, from strategic scientists to skilled workers, to attract young talent for employment and entrepreneurship in Jiangsu [5][11]. Group 5: Addressing Development Bottlenecks - The "Action Plan" proposes innovative measures to tackle challenges in urban planning, land supply, and funding for urban development [6][12]. - It suggests establishing a planning adjustment mechanism compatible with spatial governance and mixed-use development, and enhancing urban governance through comprehensive inspections [7][12]. - For land supply, it advocates a mixed-use development approach and various models for redeveloping inefficient land [12][13]. - In terms of funding, it aims to create a sustainable financing mechanism for urban construction, encouraging social capital participation alongside government support [13].

Macro Insights - The "14th Five-Year Plan" introduces three new policy ideas: the establishment of the "investment in people" concept to enhance human capital quality, a focus on "first establish then break" in policy formulation to ensure systemic resilience during the transition period, and a dual-driven approach of "innovation-driven" and "institutional openness" to reshape global competitive advantages [5]. Fixed Income - Economic data from January to February 2026 shows that the industrial added value growth rate is within the range of the same period in the past two years. Fixed asset investment growth has significantly increased after a decline since Q2 2025, and retail sales growth has also improved. The government bond yield curve has steepened, and small-cap stocks have outperformed in equity assets. Market sentiment in the bond market is under pressure due to rising inflation expectations and geopolitical tensions [6]. Banking - The newly released "Interim Measures for the Regulatory Rating of Wealth Management Companies" aims to guide the high-quality development of the wealth management industry, emphasizing risk-based and capability-oriented assessments. The market anticipates a shift towards quality improvement over quantity expansion in the wealth management sector, with an estimated annual growth of 2-3 trillion yuan, reflecting a year-on-year decrease [7]. Materials - The price of iridium has increased by 12% this week and has risen by 71% year-to-date. In contrast, prices for beryllium and neodymium oxide have decreased, while uranium prices have risen. The price of silicon for photovoltaic materials has also declined, indicating mixed trends across various new materials [8]. Hydrogen Energy - The Ministry of Industry and Information Technology, the Ministry of Finance, and the National Development and Reform Commission have jointly issued a notice to launch hydrogen energy comprehensive application pilot projects. The policy framework aims to scale down costs and establish a closed-loop ecosystem for hydrogen energy applications, with a focus on expanding application scenarios, particularly in green ammonia and industrial settings [9]. Company Performance - For the year 2025, Jiantao Laminated Board (1888.HK) reported a revenue of 20.4 billion HKD, a year-on-year increase of 10.0%, and a net profit of 2.442 billion HKD, up 83.6%. This growth is attributed to multiple price increases in copper-clad laminate products and a significant recovery in fair value gains [9]. - Qiu Tai Technology (1478.HK) achieved a revenue of 20.877 billion RMB in 2025, a 29.3% increase year-on-year, with a gross margin improvement of 1.7 percentage points to 7.8%. The net profit surged by 435.2%, driven by a focus on mid-to-high-end camera modules and expansion into automotive and IoT sectors [10].

Core Viewpoint - The "14th Five-Year Plan" emphasizes proactive policy measures to address challenges from international order restructuring, domestic demographic changes, and economic transformation, with "new productive forces" as the core engine [5]. Policy Changes - The concept of "investing in people" is fully established to enhance human capital quality, counteract the demographic turning point, and unleash consumer potential, creating a new growth driver led by domestic demand [6]. - Policy formulation focuses on "establishing before breaking," ensuring systemic resilience and bottom-line safety during the transition period. This includes enhancing industrial chain resilience and optimizing traditional industries to avoid hollowing out, while also ensuring a reliable and orderly transition from fossil to non-fossil energy sources [6]. - The dual drive of "innovation-driven" and "institutional openness" is maintained to reshape global competitive advantages. This involves accelerating technological progress to lead industrial upgrades and aligning with high-standard trade agreements, particularly in services, digital trade, and cross-border data flow [6].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of between 55 million to 75 million yuan in 2025, recovering from a loss of 156 million yuan in the previous year. This turnaround is attributed to capacity expansion, high demand for high-frequency and high-speed copper foil, and an increase in sales and proportion of high-value-added products, alongside cost reduction and efficiency improvements [3][4]. - The company has established a strong competitive barrier through its deep technical expertise and optimized production capacity. It leads the domestic market in RTF copper foil sales and has successfully launched HVLP1-3 copper foil into mass production, with HVLP4 copper foil currently undergoing performance testing [4][5]. - The company has built long-term strategic partnerships with leading firms in the downstream sectors, enhancing its brand reputation and market presence. This collaboration fosters customer loyalty and drives technological advancements, creating a positive feedback loop for sustained growth [5]. Financial Projections - Revenue projections for the company are estimated at 6.547 billion yuan in 2025, 7.320 billion yuan in 2026, and 8.112 billion yuan in 2027. The net profit attributable to shareholders is forecasted to be 739 million yuan in 2025, 3.340 billion yuan in 2026, and 5.180 billion yuan in 2027 [8][10]. - The company is expected to see a significant revenue growth rate of 38.74% in 2025, followed by 11.80% in 2026 and 10.82% in 2027 [10][11].

Macro Analysis - The economic data for January-February 2026 shows a positive start, with production, consumption, and investment growth rates exceeding market expectations. This is attributed to strong consumer performance driven by the extended Spring Festival holiday and pre-released funds for "old-for-new" exchanges, robust export performance, and improved corporate profits due to narrowing PPI declines, alongside effective investment policies from 2025 [1][2][3]. Industry Research Real Estate - As of March 15, 2026, new home transactions in 20 cities totaled 98,000 units, reflecting a decrease of 29.9%. Notable declines include Beijing at 4,764 units (-28%), Shanghai at 15,000 units (-14%), and Shenzhen at 2,866 units (-59%). In the secondary housing market, 10 cities recorded 174,000 transactions, down 8.0%, with Beijing at 30,000 units (-7%), Shanghai at 48,000 units (-2%), and Shenzhen at 9,845 units (-13%) [4]. Company Research Jiang Tao Laminated Board (1888.HK) - For the full year 2025, the company reported revenue of HKD 20.4 billion, a year-on-year increase of 10.0%, and a net profit of HKD 2.442 billion, up 83.6%. This growth is driven by multiple price increases in copper-clad laminate products, enhancing gross margins, and a significant recovery in fair value changes of equity instruments, which contributed HKD 504 million compared to a loss of HKD 79 million in 2024. The company is expected to maintain profit growth due to rising prices and potential growth in high-end electronic fabrics, leading to an upward revision of net profit forecasts for 2026-2027 by 28% and 26% to HKD 5.07 billion and HKD 6.08 billion, respectively, with a new forecast for 2028 at HKD 6.71 billion. The rating is maintained at "Buy" [5].

Group 1: Economic Development Strategies - The "14th Five-Year Plan" emphasized "innovation" and "reform," while the "15th Five-Year Plan" establishes "new quality productivity" as the core engine for economic growth[4] - The "15th Five-Year Plan" identifies three new policy changes: a comprehensive establishment of the "investment in people" concept, a focus on "establishing before breaking" in policy formulation, and a dual drive of "innovation-driven" and "institutional openness"[3] - The GDP growth target for the "15th Five-Year Plan" is set at 5% annually, reflecting a shift towards quality over quantity in economic growth[7] Group 2: Key Indicators and Goals - The urbanization rate is targeted to increase from 67.9% in 2025 to 71% by 2030, indicating a focus on urban development[7] - The plan aims for the per capita disposable income to grow by 5% annually, aligning with GDP growth[10] - The proportion of non-fossil energy in total energy consumption is expected to increase by 3.3 percentage points during the "15th Five-Year Plan" period[9] Group 3: Investment and Infrastructure - The "15th Five-Year Plan" outlines 109 major projects, an increase from 102 in the "14th Five-Year Plan," focusing on enhancing industrial resilience and green transformation[23] - The plan emphasizes the construction of a new energy system, including renewable energy sources, to ensure energy security amid geopolitical risks[25] - Investment in human resources and public services is prioritized, with a focus on improving education, healthcare, and elderly care services[30] Group 4: Consumption and Economic Interaction - The "15th Five-Year Plan" aims to significantly increase the resident consumption rate, with specific measures to enhance income and improve the consumption environment[30] - Policies will focus on expanding service consumption and improving the quality of supply to meet diverse consumer needs[31] - The plan seeks to eliminate unreasonable restrictions in the consumption sector to unleash consumer potential[32]